Showing results (1961-1970 of 2,232) with videos related to
Sort By:
Pageof 224
Journal of the National Cancer Institute|April 5, 2017
Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall SurvivalChee Khoon Lee, Lucy Davies, Yi-Long Wu, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 2, 2013
Epidermal growth factor receptor inhibition in lung cancer: status 2012Fred R Hirsch, Pasi A Jänne, Wilfried E Eberhardt, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 30, 2018
Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung CancerYi-Long Wu, James Chih-Hsin Yang, Dong-Wan Kim, et al.BMC Cancer|November 28, 2018
Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpressionRui-Lian Chen, Jun Zhao, Xu-Chao Zhang, et al.Clinical Lung Cancer|April 25, 2022
Safety of Tepotinib in Patients With MET Exon 14 Skipping NSCLC and Recommendations for ManagementRemi Veillon, Hiroshi Sakai, Xiuning Le, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 15, 2022
Expert Consensus Recommendations on Biomarker Testing in Metastatic and Nonmetastatic NSCLC in AsiaTetsuya Mitsudomi, Daniel Tan, James Chih-Hsin Yang, et al.Journal for Immunotherapy of Cancer|February 22, 2023
SAFFRON-103: a phase 1b study of the safety and efficacy of sitravatinib combined with tislelizumab in patients with locally advanced or metastatic non-small cell lung cancerJun Zhao, Xinmin Yu, Dingzhi Huang, et al.Lung Cancer (Amsterdam, Netherlands)|December 12, 2018
Clinical utility of a blood-based EGFR mutation test in patients receiving first-line erlotinib therapy in the ENSURE, FASTACT-2, and ASPIRATION studiesYi-Long Wu, Victor Lee, Chong-Kin Liam, et al.The American Journal of Surgical Pathology|December 20, 2023
Prognostic Value of Immunohistochemistry-based Subtyping Before and After Neoadjuvant Chemotherapy in Patients with Triple-negative Breast CancerLong Wu, Minyan Chen, Yuxiang Lin, et al.The Patient|November 28, 2017
Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6)Yi-Long Wu, Vera Hirsh, Lecia V Sequist, et al.Pageof 224